Conflict of interest: none declared.
Clinical dermatology •Concise report
Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema
Article first published online: 25 JUN 2012
© The Author(s). CED © 2012 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 38, Issue 2, pages 151–153, March 2013
How to Cite
Pressler, A., Grosber, M., Halle, M., Ring, J. and Brockow, K. (2013), Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clinical and Experimental Dermatology, 38: 151–153. doi: 10.1111/j.1365-2230.2012.04430.x
- Issue published online: 12 FEB 2013
- Article first published online: 25 JUN 2012
- Accepted for publication 11 February 2012
Vibratory angio-oedema is a rare form of physical urticaria characterized by pruriginous weals and angio-oedema at the site of exposure to vibration. Severe treatment-resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti-IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio-oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment-resistant vibratory angio-oedema.